Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Current price $0.7665
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 8, 26 |
Daily · Wilder smoothing
| HC Wainwright & Co. |
| maintain |
| Buy |
| Buy |
| Oct 2, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Sep 30, 26 | BTIG | maintain | Buy | Buy |
| Sep 22, 26 | Oppenheimer | maintain | Outperform | Outperform |
| Sep 17, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Sep 16, 26 | Canaccord Genuity | maintain | Buy | Buy |
| Sep 15, 26 | BTIG | maintain | Buy | Buy |
| Jun 26, 26 | Piper Sandler | upgrade | Neutral | Overweight |
| Jun 25, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 27.49 | Oscillator | Buy |
| Stochastic %K (14, 3, 3) | 9.98 | Oscillator | Buy |
| Williams %R (14) | -86.04 | Oscillator | Buy |
| MACD (12, 26, 9) | -0.18 (Hist 0.03) | Oscillator | Buy |
| Average Directional Index (14) | 12.07 (+DI 18.9 / -DI 27.4) | Trend | Neutral |
| EMA 20 | 0.97 | MA | Strong Sell |
| SMA 20 | 0.91 | MA | Strong Sell |
| EMA 50 | 1.35 | MA | Strong Sell |
| SMA 50 | 1.52 | MA | Strong Sell |
| SMA 200 | 2.23 | MA | Strong Sell |
TTM vs. 5-year historical average (annual ratios)
| Metric | CNTB | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -0.9x | -1.8x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -0.8x | EPS est. -1.01 | In line |
| Price / Book | 1.8x | 1.3x | Elevated |
| Price / Sales | 16.4x | 491.1x | Discount |
| EV / EBITDA | -0.4x | -0.2x | Elevated |
| Return on equity | -150.5% | — | Weak |
| Gross margin | 100.0% | 40.0% | Above hist. |
| Debt / Equity | 0.02 | 0.01 | Conservative |
| Piotroski / Altman Z | 2/9 | Z -15.63 | Distress |
Discounted cash flow model
FY2025 · 10-K disclosure
Stock news · updated daily
Connect Biopharma Holdings Limited (CNTB) Discusses Rademikibart and SEABREEZE Trial Results in Acute COPD Transcript
Connect Biopharma Holdings (CNTB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Connect Biopharma Holdings (CNTB) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Inhibrx Biosciences (NASDAQ: INBX - Get Free Report) and Connect Biopharma (NASDAQ: CNTB - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability and risk. Volatility and Risk Inhibrx Biosciences has a
Connect Biopharma NASDAQ: CNTB reported top-line results from its Seabreeze STAT Phase II study of rademikibart in patients experiencing acute exacerbations of chronic obstructive pulmonary disease, or COPD. The company said the study met its primary objective, showing reductions in treatment failures during the month after an exacerbation.
Connect Biopharma Holdings Limited (NASDAQ:CNTB) recently shared positive topline results from its global Phase 2 study.
Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Seabreeze STAT Study Evaluating Rademikibart for COPD Exacerbations Transcript
– Rademikibart significantly reduced the rate of treatment failure compared to placebo through one month by 81% (p=0.0122) –
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 12, 2026 | -0.31 | -0.27 | Beat 14.3% | $2.75M |
| May 12, 2026 | -0.29 | -0.34 | Miss -17.2% | $24.42K |
| Mar 31, 2026 | -0.30 | -0.27 | Beat 10.0% | — |
| Nov 12, 2025 | -0.03 | -0.04 | Miss -29.7% | — |
| Aug 13, 2025 | -0.22 | -0.03 | Beat 85.4% | $48.00K |
| May 15, 2025 | -0.26 | -0.03 | Beat 89.9% | — |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Sep 30, 26 | Xanthopoulos Kleanthis Gabriel | director | A-Award | 5,000 | — |
| Sep 30, 26 |
| Liu Jean I |
| director |
| A-Award |
| 8,984 |
| — |
| Jun 30, 26 | Xanthopoulos Kleanthis Gabriel | director | A-Award | 3,738 | — |
| Jun 30, 26 | Liu Jean I | director | A-Award | 6,718 | — |
| May 29, 26 | Huang James | director | P-Purchase | 150,000 @ $2.48 | $371.6K |
| Mar 31, 26 | Xanthopoulos Kleanthis Gabriel | director | A-Award | 2,816 | — |
| Mar 31, 26 | Liu Jean I | director | A-Award | 5,061 | — |
| Mar 31, 26 | Huang James | director | P-Purchase | 1,160,000 @ $3.45 | $4.00M |
| 8-K | Sep 15, 2026 | 2026-09-15 07:06:34 | View |
| SC 13G/A | Aug 14, 2026 | 2026-08-14 21:24:50 | View |
| SC 13G/A | Aug 14, 2026 | 2026-08-14 10:45:14 | View |
| 10-Q | Aug 12, 2026 | 2026-08-12 16:16:30 | View |
| 8-K | Aug 12, 2026 | 2026-08-12 16:13:33 | View |
| 4 | Jul 1, 2026 | 2026-07-01 16:26:58 | View |
Proxy statement (DEF 14A) disclosures